Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR1 | Q9BXC0 | 16/20 | 0.35 |
| ▸ | APAF1 | O14727 | 1/20 | 0.35 |
| ▸ | CASP6 | P55212 | 1/20 | 0.35 |
| ▸ | ENPP1 | P22413 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30498462 | 1.00 | HCAR1 (0.35) | HCAR1APAF1CASP6ENPP1 | |
| SCHEMBL167394 | 0.72 | MAPK1 (0.46) | HCAR1 | |
| SCHEMBL29623547 | 0.72 | MAPK1 (0.46) | HCAR1 | |
| SCHEMBL17489428 | 0.67 | HCAR1 (0.38) | HCAR1 | |
| SCHEMBL29578870 | 0.65 | PDE3B (0.46) | — | |
| SCHEMBL23326745 | 0.64 | ENPP1 (0.44) | ENPP1 | |
| SCHEMBL217007 | 0.64 | PDE3B (0.48) | ENPP1 | |
| SCHEMBL29362624 | 0.64 | PDE3B (0.48) | ENPP1 | |
| SCHEMBL1109019 | 0.63 | HCAR1 (0.33) | HCAR1 | |
| SCHEMBL8266929 | 0.63 | PDE3B (0.32) | HCAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6683183-B2 | BICYCLIC HETEROCYCLES THAT INHIBIT CYCLIN-DEPENDENT KINASE OR TYROSINE KINASE ENZYMES, OR BOTH, FOR TREATMENT OF PROLIFERATIVE DISORDERS | WARNER-LAMBERT COMPANY | 2004-01-27 | — | — | US | disclosed |
| US-20020061865-A1 | Pyridotriazines and pyridopyridazines | KRAMER JAMES BERNARD (US) | 2002-05-23 | — | — | US | disclosed |
| EP-1195378-A1 | Pyridotriazines and pyridopyridazines | WARNER-LAMBERT COMPANY (US) | 2002-04-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020061865-A1 | Pyridotriazines and pyridopyridazines | CDK1, CDK4, CDK2 | HCAR1 1040/4885APAF1 1557/4885CASP6 3138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.